

(FILE 'HOME' ENTERED AT 17:14:50 ON 19 JAN 2007)

FILE 'REGISTRY' ENTERED AT 17:15:27 ON 19 JAN 2007

L1 STRUCTURE UPLOADED  
L2 50 SEA SSS SAM L1  
DISPLAY L2 1-50

FILE 'REGISTRY' ENTERED AT 17:18:06 ON 19 JAN 2007

L3 STRUCTURE UPLOADED  
L4 50 SEA SSS SAM L3  
DISPLAY L4 1-5 ALL

FILE 'REGISTRY' ENTERED AT 17:25:33 ON 19 JAN 2007

SET LINE 250  
SET DETAIL OFF  
E "HYDROXYGLYCINAMIDE"/CN 25  
E "HYDROXYLGLYCINAMIDE"/CN 25  
E "HYDROXY LGLYCINE AMIDE"/CN 25  
E "HYDROXY GLYCINE AMIDE"/CN 25  
E "GLYCINE AMIDE"/CN 25  
SET NOTICE 1000 SEARCH  
L5 1 SEA ABB=ON PLU=ON "GLYCINE AMIDE"/CN  
SET NOTICE 1 DISPLAY  
SET LINE LOGIN  
SET DETAIL LOGIN  
DIS L5 1 SQIDE  
SET NOTICE LOGIN DISPLAY  
SET NOTICE LOGIN SEARCH  
L6 79 SEA ABB=ON PLU=ON C2H6N2O2/MF  
DISPLAY L6 1-79 ALL

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 JAN 2007 HIGHEST RN 917867-30-2

DICTIONARY FILE UPDATES: 18 JAN 2007 HIGHEST RN 917867-30-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> display l6 9 all

L6 ANSWER 9 OF 79 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 748135-32-2 REGISTRY  
ED Entered STN: 20 Sep 2004  
→CN Acetamide, 2-amino-2-hydroxy- (9CI) (CA INDEX NAME)  
→MF C2 H6 N2 O2  
CI COM

SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
 DT.CA Caplus document type: Patent  
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)  
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)



Predicted Properties (PPROP)

PROPERTY (CODE)	VALUE	CONDITION	NOTE
Bioconc. Factor (BCF)	1.0	pH 1 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 2 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 3 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 4 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 5 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 6 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 7 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 8 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 9 25 deg C	(1)
Bioconc. Factor (BCF)	1.0	pH 10 25 deg C	(1)
Boiling Point (BP)	379.0+/-37.0 deg C	760 Torr	(1)
Density (DEN)	1.409+/-0.06 g/cm**3	760 Torr	(1)
Enthalpy of Vap. (HVAP)	72.53+/-6.0 kJ/mol	760 Torr	(1)
Flash Point (FP)	183.0+/-26.5 deg C		(1)
Freely Rotatable Bonds (FRB)	3		(1)
H acceptors (HAC)	4		(1)
H donors (HD)	5		(1)
Hydrogen Donors/Acceptors Sum (HDAS)	9		(1)
Koc (KOC)	1.0	pH 1 25 deg C	(1)
Koc (KOC)	1.0	pH 2 25 deg C	(1)
Koc (KOC)	1.0	pH 3 25 deg C	(1)
Koc (KOC)	1.0	pH 4 25 deg C	(1)
Koc (KOC)	1.0	pH 5 25 deg C	(1)
Koc (KOC)	1.0	pH 6 25 deg C	(1)
Koc (KOC)	1.52	pH 7 25 deg C	(1)
Koc (KOC)	2.47	pH 8 25 deg C	(1)
Koc (KOC)	2.63	pH 9 25 deg C	(1)
Koc (KOC)	2.63	pH 10 25 deg C	(1)
LOGD (LOGD)	-4.85	pH 1 25 deg C	(1)
LOGD (LOGD)	-4.84	pH 2 25 deg C	(1)
LOGD (LOGD)	-4.78	pH 3 25 deg C	(1)
LOGD (LOGD)	-4.42	pH 4 25 deg C	(1)
LOGD (LOGD)	-3.60	pH 5 25 deg C	(1)
LOGD (LOGD)	-2.67	pH 6 25 deg C	(1)
LOGD (LOGD)	-1.99	pH 7 25 deg C	(1)
LOGD (LOGD)	-1.78	pH 8 25 deg C	(1)
LOGD (LOGD)	-1.75	pH 9 25 deg C	(1)
LOGD (LOGD)	-1.75	pH 10 25 deg C	(1)
LOGP (LOGP)	-1.745+/-0.476	25 deg C	(1)
Mass Intrinsic Solubility (ISLB.MASS)	230 g/L	25 deg C	(1)

Mass Solubility (SLB.MASS)	999.9 g/L	pH 1 25 deg C	(1)
Mass Solubility (SLB.MASS)	999.9 g/L	pH 2 25 deg C	(1)
Mass Solubility (SLB.MASS)	999.9 g/L	pH 3 25 deg C	(1)
Mass Solubility (SLB.MASS)	999.9 g/L	pH 4 25 deg C	(1)
Mass Solubility (SLB.MASS)	999.9 g/L	pH 5 25 deg C	(1)
Mass Solubility (SLB.MASS)	999.9 g/L	pH 6 25 deg C	(1)
Mass Solubility (SLB.MASS)	398 g/L	pH 7 25 deg C	(1)
Mass Solubility (SLB.MASS)	246 g/L	pH 8 25 deg C	(1)
Mass Solubility (SLB.MASS)	231 g/L	pH 9 25 deg C	(1)
Mass Solubility (SLB.MASS)	231 g/L	pH 10 25 deg C	(1)
Mass Solubility (SLB.MASS)	230 g/L	Unbuffered Water	(1)
		pH 9.50	
		25 deg C	
Molar Intrinsic Solubility (ISLB.MOL)	2.55 mol/L	25 deg C	(1)
Molar Solubility (SLB.MOL)	11.10 mol/L	pH 1 25 deg C	(1)
Molar Solubility (SLB.MOL)	11.10 mol/L	pH 2 25 deg C	(1)
Molar Solubility (SLB.MOL)	11.10 mol/L	pH 3 25 deg C	(1)
Molar Solubility (SLB.MOL)	11.10 mol/L	pH 4 25 deg C	(1)
Molar Solubility (SLB.MOL)	11.10 mol/L	pH 5 25 deg C	(1)
Molar Solubility (SLB.MOL)	11.10 mol/L	pH 6 25 deg C	(1)
Molar Solubility (SLB.MOL)	4.42 mol/L	pH 7 25 deg C	(1)
Molar Solubility (SLB.MOL)	2.73 mol/L	pH 8 25 deg C	(1)
Molar Solubility (SLB.MOL)	2.56 mol/L	pH 9 25 deg C	(1)
Molar Solubility (SLB.MOL)	2.56 mol/L	pH 10 25 deg C	(1)
Molar Solubility (SLB.MOL)	2.55 mol/L	Unbuffered Water	(1)
		pH 9.50	
		25 deg C	
Molar Volume (MVOL)	63.9+/-3.0 cm**3/mol	20 deg C	(1)
		760 Torr	
Molecular Weight (MW)	90.08		(1)
PKA (PKA)	12.12+/-0.20	Most Acidic	(1)
		25 deg C	
PKA (PKA)	6.87+/-0.50	Most Basic	(1)
		25 deg C	
Polar Surface Area (PSA)	89.34 A**2		(1)
Vapor Pressure (VP)	2.67E-07 Torr	25 deg C	(1)

(1) Calculated using Advanced Chemistry Development (ACD/Labs) Software V8.19  
((C) 1994-2007 ACD/Labs)

See HELP PROPERTIES for information about property data sources in REGISTRY.

2 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

*Applicat*

AN 142:441834 CA  
 TI Identification of compounds that inhibit replication of human immunodeficiency virus  
 IN Balzarini, Jan Maria Rene; Vahlne, Anders; Hogberg, Marita; Tong, Weimin  
 PA Belg.  
 SO U.S. Pat. Appl. Publ., 91 pp., Cont.-in-part of U.S. Ser. No. 783,053.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-53  
 ICS A61K031-513; A61K031-495; A61K031-445  
 NCL 514242000  
 CC 1-5 (Pharmacology)  
 Section cross-reference(s): 63  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005096319	A1	20050505	US 2004-920831	20040818
	US 2004180893	A1	20040916	US 2004-783053	20040219
	WO 2006030323	A2	20060323	WO 2005-IB3755	20050816
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006188920	A1	20060824	US 2006-409671	20060424
	US 2006183748	A1	20060817	US 2006-410633	20060425

PRAI US 2003-449494P 20030221  
 US 2003-493893P 20030808  
 US 2003-505217P 20030922  
 US 2004-783053 20040219  
 WO 2004-IB865 20040219  
 US 2004-920831 20040818

AB The present invention relates to the discovery of a novel class of compds. that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compds. More specifically, it has been found that enzymically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compds. that inhibit HIV, methods to isolate and synthesize modified glycinamide compds., and therapeutic compns. comprising these compds.

ST replication human immunodeficiency virus hydroxyglycinamide

IT Drug delivery systems  
 (capsules; identification of compds. that inhibit replication of human immunodeficiency virus)

IT Drug delivery systems  
 (gels; identification of compds. that inhibit replication of human immunodeficiency virus)

IT Antiviral agents  
 Blood analysis  
 Drug bioavailability  
 Human  
 Human coxsackievirus B4  
 Human herpesvirus 1  
 Human herpesvirus 2  
 Human immunodeficiency virus 1  
 Human parainfluenza virus 3  
 Phaseolus vulgaris  
 Punta Toro virus  
 Reovirus 1  
 Sindbis virus  
 T cell (lymphocyte)  
 Urine analysis  
 Vaccinia virus  
 Vesicular stomatitis virus  
 (identification of compds. that inhibit replication of human immunodeficiency virus)

IT Drug delivery systems  
 (injections, i.v.; identification of compds. that inhibit replication of human immunodeficiency virus)

IT Drug delivery systems  
 (oral; identification of compds. that inhibit replication of human

immunodeficiency virus)

IT Drug delivery systems  
(powders; identification of compds. that inhibit replication of human immunodeficiency virus)

IT Drug delivery systems  
(prodrugs; identification of compds. that inhibit replication of human immunodeficiency virus)

IT Drug delivery systems  
(tablets; identification of compds. that inhibit replication of human immunodeficiency virus)

IT 748135-32-2P  
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 56-40-6, Glycine, biological studies 56-41-7, L-Alanine, biological studies 61-90-5, L-Leucine, biological studies 107-15-3, Ethylenediamine, biological studies 147-85-3, L-Proline, biological studies 328-38-1, D-Leucine 598-41-4, Glycinamide 616-29-5, 1,3-Diamino-2-hydroxypropane 687-51-4, L-Leucinamide 729-24-8 2058-58-4, D-Asparagine 2280-40-2, L-Threoninamide 2788-83-2, L-Argininamide 4540-60-7, L-Valinamide 4985-46-0, L-Tyrosinamide 5241-58-7, L-Phenylalaninamide 6250-76-6, Sarcosinamide 6720-02-1 6791-49-7, L-Serinamide 7324-05-2, L-Alaninamide 7531-52-4, L-Prolinamide 13079-20-4, DL-Leucinamide 13123-70-1, 1,4-Diamino-2-butanone 14445-54-6, L-Isoleucinamide 16748-73-5, L-Asparaginamide 16992-40-8 17193-31-6, DL-Phenylalaninamide 17756-51-3 17756-52-4 20696-57-5, L-Tryptophanamide 22356-89-4, Glycine methylamide 23645-02-5 32388-19-5, L-Lysinamide 36791-04-5, Ribavirin 49705-99-9, L-Threoninamide 54262-83-8 67934-84-3 69304-47-8, BVDU 82410-32-0, DHPG 105301-27-7 123796-46-3, Aziridinethione 126675-52-3 139138-91-3 141497-12-3 748135-33-3 748135-34-4 748135-35-5 748135-40-2 757242-72-1 850635-17-5 850635-18-6  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 475106-70-8P  
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 132629-33-5P 150749-04-5P 150749-05-6P 150749-06-7P 150749-11-4P 748135-41-3P 748135-42-4P  
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 563-96-2, Glyoxylic acid monohydrate 4248-19-5, tert-Butyl carbamate 19757-97-2 84418-43-9  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 96-35-5P 150749-03-4P 748135-37-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 850844-65-4 850844-66-5 850844-67-6 850844-68-7 850844-69-8 850844-70-1 850844-71-2 850844-72-3 850844-73-4 850844-74-5 850844-75-6 850844-76-7 850844-77-8 850844-78-9 850844-79-0 850844-80-3 850844-81-4  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(nucleotide sequence; identification of compds. that inhibit replication of human immunodeficiency virus)

IT 850845-98-6 850845-99-7  
 RL: PRP (Properties)  
 (unclaimed nucleotide sequence; identification of compds. that inhibit replication of human immunodeficiency virus)

IT 850845-96-4 850845-97-5  
 RL: PRP (Properties)  
 (unclaimed protein sequence; identification of compds. that inhibit replication of human immunodeficiency virus)

REFERENCE 2

AN 141:218926 CA  
 TI Glycinamide derivatives for inhibiting HIV replication  
 IN Balzarini, Jan Maria Rene; Vahlne, Anders; Hogberg, Marita; Tong, Weimin  
 PA Tripep AB, Swed.  
 SO PCT Int. Appl., 92 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-164  
 ICS A61K038-06; A61P031-18  
 CC 1-5 (Pharmacology)  
 Section cross-reference(s): 34, 63

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004073703	A1	20040902	WO 2004-IB865	20040219
	WO 2004073703	B1	20041104		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2004212786	A1	20040902	AU 2004-212786	20040219
	CA 2515679	A1	20040902	CA 2004-2515679	20040219
	EP 1603546	A1	20051214	EP 2004-712638	20040219
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1777414	A	20060524	CN 2004-80010780	20040219
	JP 2006518373	T	20060810	JP 2006-502493	20040219
	US 2006183748	A1	20060817	US 2006-410633	20060425
PRAI	US 2003-449494P		20030221		
	US 2003-493893P		20030808		
	US 2003-505217P		20030922		
	US 2004-783053		20040219		
	WO 2004-IB865		20040219		
	US 2004-920831		20040818		
AB	The invention relates to the discovery of a novel class of compds. that inhibit the replication of human immunodeficiency virus (HIV), as well as approaches to identify these compds. More specifically, it has been found that enzymically prepared $\alpha$ -hydroxyglycinamide and synthetically prepared $\alpha$ -hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compds. that inhibit HIV, methods to isolate and synthesize modified glycinamide compds., and therapeutic compns. comprising these compds.				
ST	HIV replication inhibitor glycinamide deriv prepn; hydroxyglycinamide HIV replication inhibitor				
IT	Cell (extract, incubation with; glycinamide derivs. for inhibiting HIV				

replication)

IT AIDS (disease)  
 Anti-AIDS agents  
 Antiviral agents  
 Cation exchange chromatography  
 Drug delivery systems  
 Drug screening  
 Human  
 Human coxsackievirus B4  
 Human herpesvirus 1  
 Human herpesvirus 2  
 Human immunodeficiency virus  
 Human immunodeficiency virus 1  
 Human immunodeficiency virus 2  
 Human parainfluenza virus 3  
 Lymphocyte  
 Punta Toro virus  
 Reovirus 1  
 Respiratory syncytial virus  
 Sindbis virus  
 T cell (lymphocyte)  
 Vaccinia virus  
 Vesicular stomatitis virus  
 (glycinamide derivs. for inhibiting HIV replication)

IT Mus  
 (incubation with serum of; glycinamide derivs. for inhibiting HIV replication)

IT Bos taurus  
 Canis familiaris  
 Equus caballus  
 Felis catus  
 Sus scrofa domestica  
 (incubation with serum or plasma of; glycinamide derivs. for inhibiting HIV replication)

IT Ape  
 Monkey  
 (incubation with simian serum or plasma; glycinamide derivs. for inhibiting HIV replication)

IT Blood plasma  
 Blood serum  
 (incubation with; glycinamide derivs. for inhibiting HIV replication)

IT 54249-88-6  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (glycinamide derivs. for inhibiting HIV replication)

IT 748135-38-8  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (glycinamide derivs. for inhibiting HIV replication)

IT 748803-81-8, Partisphere SCX  
 RL: MSC (Miscellaneous)  
 (glycinamide derivs. for inhibiting HIV replication)

IT 56-40-6, Glycine, biological studies 56-41-7, L-Alanine, biological studies 61-90-5, L-Leucine, biological studies 107-15-3, Ethylene diamine, biological studies 147-85-3, L-Proline, biological studies 328-38-1, D-Leucine 515-94-6 616-29-5, 1,3-Diamino-2-hydroxypropane 687-51-4, L-Leucinamide 729-24-8 2058-58-4, D-Asparagine 2788-83-2, L-Argininamide 4510-08-1, L-Methioninamide 4540-60-7, L-Valinamide 4985-46-0, L-Tyrosinamide 5241-58-7, L-Phenylalaninamide 6250-76-6, Sarcosinamide 6720-02-1, DL-Tryptophanamide 6791-49-7, L-Serinamide 7324-05-2, L-Alaninamide 7531-52-4, L-Prolinamide 13079-20-4, DL-Leucinamide 13123-70-1, 1,4-Diamino-2-butanone 14445-54-6, L-Isoleucinamide 16748-73-5, L-Asparaginamide 17193-31-6, DL-Phenylalaninamide 20696-57-5, L-Tryptophanamide 22356-89-4, Glycine methylamide 23645-02-5, 1,3-Diaminoacetone 32388-19-5, L-Lysinamide

49705-99-9, L-Threoninamide 105301-27-7 123796-46-3, Aziridinethione  
126675-52-3 136259-22-8

RL: PAC (Pharmacological activity); BIOL (Biological study)  
(glycinamide derivs. for inhibiting HIV replication)

IT 598-41-4D, Glycinamide, derivs. 67934-84-3 748135-32-2 748135-32-2D,  
derivs. 748135-33-3 748135-34-4 748135-35-5 748135-36-6  
748135-39-9 748135-40-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(glycinamide derivs. for inhibiting HIV replication)

IT 64-17-5, Ethanol, reactions 67-56-1, Methanol, reactions 67-63-0,  
Isopropyl alcohol, reactions 563-96-2 621-84-1, Benzyl carbamate  
4248-19-5, tert-Butyl carbamate 7647-01-0, Hydrochloric acid, reactions  
7664-41-7, Ammonia, reactions 84418-43-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(glycinamide derivs. for inhibiting HIV replication)

IT 4746-62-7P 19757-97-2P 132629-33-5P 150749-03-4P 150749-04-5P  
475106-70-8P 748135-37-7P 748135-41-3P 748135-42-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(glycinamide derivs. for inhibiting HIV replication)

IT 150749-05-6P 150749-06-7P 150749-09-0P 150749-10-3P 150749-11-4P,  
 $\alpha$ -Hydroxyglycinamide hydrochloride 150749-12-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(glycinamide derivs. for inhibiting HIV replication)

=>